Multus Overview

  • Status
  • Private

  • Employees
  • 27

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Latest Deal Amount
  • $300K

  • Investors
  • 26

Multus General Information

Description

Developer of a biotechnology platform designed to accelerate the development of high-performance cell culture media for biomanufacturing. The company offers AI-driven, high-throughput robotic automation and an expert team of scientists and engineers, enabling biomanufacturers to enhance efficiency, strengthen supply chain reliability, and advance the production of next-generation therapies, food, and materials.

Contact Information

Website
www.multus.bio
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Translation & Innovation Hub
  • 84 Wood Lane
  • London W12 0BZ
  • England, United Kingdom
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Corporate Office
  • Translation & Innovation Hub
  • 84 Wood Lane
  • London W12 0BZ
  • England, United Kingdom

Multus Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Multus Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
17. Accelerator/Incubator 26-May-2026 $300K Completed Generating Revenue
16. Early Stage VC (Series A) 16-Jan-2023 Completed Generating Revenue
15. Grant 23-Mar-2022 Completed Generating Revenue
14. Accelerator/Incubator Completed Generating Revenue
13. Accelerator/Incubator Completed Generating Revenue
12. Accelerator/Incubator Completed Generating Revenue
11. Seed Round 19-Jul-2021 Completed Generating Revenue
10. Grant 31-Mar-2021 Completed Generating Revenue
9. Accelerator/Incubator 01-Jan-2021 Completed Generating Revenue
8. Grant 01-Jan-2021 $150K Completed Generating Revenue
To view Multus’s complete valuation and funding history, request access »

Multus Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
Series A
Ordinary A 38,461 $0.000001 $4.68 $4.68 1x $4.68 1.87%
To view Multus’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Multus Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a biotechnology platform designed to accelerate the development of high-performance cell culture media for
Biotechnology
London, United Kingdom
27 As of 2026

Junction City, KS
 

Braunschweig, Germany
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Multus Competitors (2)

One of Multus’s 2 competitors is InVitria, a Corporation company based in Junction City, KS.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
InVitria Corporation Junction City, KS
Abcalis Accelerator/Incubator Backed Braunschweig, Germany
You’re viewing 2 of 2 competitors. Get the full list »

Multus Patents

Multus Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202218985-D0 Engineered epidermal growth factor variants Inactive 15-Dec-2022
EP-4634210-A1 Engineered platelet-derived growth factor variants Pending 15-Dec-2022
GB-202218987-D0 Engineered platelet-derived growth factor variants Pending 15-Dec-2022
GB-2637896-A Engineered platelet-derived growth factor variants Pending 15-Dec-2022
US-20260201004-A1 Engineered platelet-derived growth factor variants Pending 15-Dec-2022 C07K14/49
To view Multus’s complete patent history, request access »

Multus Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Multus Investors (26)

Investor Name Investor Type Holding Investor Since Participating Rounds
MedTech Innovator Accelerator/Incubator Minority
Asahi Kasei Corporate Venture Capital Corporate Venture Capital Minority
Big Idea Ventures Venture Capital Minority
Mandi Ventures Venture Capital Minority
Nourish Ventures Corporate Venture Capital Minority
You’re viewing 5 of 26 investors. Get the full list »

Multus FAQs

  • Where is Multus headquartered?

    Multus is headquartered in London, United Kingdom.

  • What is the size of Multus?

    Multus has 27 total employees.

  • What industry is Multus in?

    Multus’s primary industry is Biotechnology.

  • Is Multus a private or public company?

    Multus is a Private company.

  • What is Multus’s current revenue?

    The current revenue for Multus is .

  • How much funding has Multus raised over time?

    Multus has raised $12.9M.

  • Who are Multus’s investors?

    MedTech Innovator, Asahi Kasei Corporate Venture Capital, Big Idea Ventures, Mandi Ventures, and Nourish Ventures are 5 of 26 investors who have invested in Multus.

  • Who are Multus’s competitors?

    InVitria and Abcalis are competitors of Multus.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process